Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Puschner, B.
Vauth, R.
Jacobi, F.
and
Becker, T.
2006.
Bedeutung von Psychotherapie in der Versorgung von Menschen mit schizophrenen Störungen in Deutschland.
Der Nervenarzt,
Vol. 77,
Issue. 11,
p.
1301.
Haro, Josep Maria
Novick, Diego
Belger, Mark
and
Jones, Peter B.
2006.
Antipsychotic type and correlates of antipsychotic treatment discontinuation in the outpatient treatment of schizophrenia.
European Psychiatry,
Vol. 21,
Issue. 1,
p.
41.
María Haro, Joseph
Novick, Diego
Belger, Mark
and
Jones, Peter B.
2006.
Tipo de antipsicótico y correlatos de la interrupción del tratamiento de antipsicóticos en el tratamiento ambulatorio de la esquizofrenia.
European psychiatry (Ed. Española),
Vol. 13,
Issue. 5,
p.
236.
Tarricone, Ilaria
Casoria, Michela
Gozzi, Beatrice Ferrari
Grieco, Daniela
Menchetti, Marco
Serretti, Alessandro
Ujkaj, Manjola
Pastorelli, Francesca
and
Berardi, Domenico
2006.
Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a community mental health centre.
BMC Psychiatry,
Vol. 6,
Issue. 1,
Vauth, Roland
and
Stieglitz, Rolf-Dieter
2006.
Der Stellenwert von Kombinationsbehandlung in der Versorgung schizophrener Störungen.
Zeitschrift für Psychiatrie, Psychologie und Psychotherapie,
Vol. 54,
Issue. 3,
p.
173.
Nuss, Philippe
Hummer, Martina
and
Tessier, Cédric
2007.
The use of amisulpride in the treatment of acute psychosis.
Therapeutics and Clinical Risk Management,
Vol. 3,
Issue. 1,
p.
3.
Carlo Altamura, A.
Bobo, William V.
and
Meltzer, Herbert Y.
2007.
Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment.
International Clinical Psychopharmacology,
Vol. 22,
Issue. 5,
p.
249.
Markopoulou, Maria
Georgiadou, Olga
Tsiftsoglou, Keranio
and
Bobotas, Konstantinos
2008.
Metabolic monitoring of psychiatric patients on second-generation antipsychotics.
Annals of General Psychiatry,
Vol. 7,
Issue. S1,
Tarricone, Ilaria
Serretti, Alessandro
Gozzi, Beatrice Ferrari
Mandelli, Laura
Grieco, Daniela
Mellini, Lorenzo
Biagini, Stefano
Berti, Beatrice
and
Berardi, Domenico
2008.
Metabolic side effects of second generation antipsychotic agents in antipsychotic-naïve patients: One-month prospective evaluation.
Psychiatry Research,
Vol. 157,
Issue. 1-3,
p.
269.
Peuskens, J.
Gillain, B.
De Graeve, D.
Van Vleymen, B.
and
Albert, A.
2009.
Belgian Schizophrenia Outcome Survey – Results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol.
European Psychiatry,
Vol. 24,
Issue. 3,
p.
154.
McEvoy, Joseph P
Zigman, Daniel
and
Margolese, Howard C
2010.
First- and Second-Generation Antipsychotics.
The Canadian Journal of Psychiatry,
Vol. 55,
Issue. 3,
p.
144.
Citrome, Leslie
2012.
A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia.
Expert Opinion on Pharmacotherapy,
Vol. 13,
Issue. 11,
p.
1545.
Miyamoto, Seiya
Merrill, David B.
Fredrik Jarskog, L.
Wolfgang Fleishhacker, W.
Marder, Stephen R.
and
Lieberman, Jeffrey A.
2015.
Psychiatry.
p.
2088.
Comments
No Comments have been published for this article.